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ABSTRACT  32 
Background: Brown macroalgae have attracted attention because they display a wide 33 
range of biological activities, including antitumoral properties. In a previous screen we 34 
isolated isololiolide from Cystoseira tamariscifolia for the first time. 35 
Purpose: To examine the therapeutical potential of isololiolide against tumor cell lines. 36 
Methods/Study design: The structure of the compound was established and confirmed by 37 
1D and 2D NMR as well as HRMS spectral analysis. The in vitro cytotoxicity was 38 
analyzed by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 39 
assay in tumoral as well as in non-tumoral cell lines. Cell cycle arrest and induction of 40 
apoptosis were assessed by flow cytometry. Alteration of expression levels in proteins 41 
important in the apoptotic cascade was analyzed by western blotting. 42 
Results: Isololiode was isolated for the first time from the brown macroalga Cystoseira 43 
tamariscifolia.  Isololiolide exhibited significant cytotoxic activity against three human 44 
tumoral cell lines, namely hepatocarcinoma HepG2 cells, whereas no cytotoxicity was 45 
found in non-malignant MRC-5 and HFF-1 human fibroblasts. Isololiode completely 46 
disrupted the HepG2 normal cell cycle and induced significant apoptosis. Moreover, 47 
Western blot analysis showed that isololiode altered the expression of proteins that are 48 
important in the apoptotic cascade, namely increasing PARP cleavage and p53 expression 49 
while decreasing procaspase-3 and Bcl-2 levels.  50 
Conclusion: Isololiolide isolated from C. tamariscifolia is able to exert a selective 51 
cytotoxic activity on hepatocarcinoma HepG2 cells as well as induce apoptosis through 52 
the modulation of apoptosis-related proteins. 53 
 54 
Keywords: Marine natural product; Cystoseira; Isololiolide; Carotenoid metabolite; Cell 55 
cycle; Apoptosis 56 
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Abbreviations: 1D and 2D NMR, one-dimensional and two-dimensional nuclear 57 
magnetic resonance; 1H and 13C NMR, proton and carbon-13 nuclear magnetic resonance; 58 
ANOVA, analysis of variance; Bak, Bcl-2 homologous antagonist killer; Bax, Bcl-2-59 
associated X protein; Bcl-2, B-cell lymphoma 2; CDCl3, deuterated chloroform; CNT, 60 
compound-induced cytotoxicity on non-tumoral cells; CT, compound-induced 61 
cytotoxicity on tumoral cells; DEPT, distortionless enhancement by polarization transfer; 62 
DMEM, Dulbecco's Modified Eagle's medium; DMSO, dimethyl sulfoxide; ECL, 63 
enhanced chemiluminescence; EDTA, ethylenediaminetetraacetic acid; EtOAc, ethyl 64 
acetate; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; HCC, hepatocellular 65 
carcinoma; HPLC, high performance liquid chromatography; HRESIMS, high-resolution 66 
electrospray ionisation mass spectrometry; HRMS, high resolution mass spectrometry; 67 
HRP, horseradish peroxidase; HSD, honest significant difference; IC50, half maximal 68 
inhibitory concentration; m/z, mass-to-charge ratio; MeOH, methanol; MTT, 3-(4,5-69 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NP-40, nonidet P-40; p53, 70 
protein 53; PARP, poly (ADP-ribose) polymerase; PI, propidium iodide; RPMI, Roswell 71 
Park Memorial Institute medium; SARs, structure-activity relationships; SDS, sodium 72 
dodecyl sulphate; SEM, standard error of mean; SiO2, silica; TLC, thin layer 73 
chromatography; TMS, tetramethylsilane; WHO, World Health Organization. 74 
  75 
 76 
 77 
 78 
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Introduction 81 
Cancer is a major public health problem with an estimated prevalence of about 3% in 82 
Europe, increasing to 15% at old age. Moreover, cancer related deaths are estimated to 83 
increase to over 11 million in 2030 (WHO, 2010). Hepatocellular carcinoma (HCC) is 84 
the third leading cause of cancer-related death worldwide, after lung and stomach cancer 85 
(Ferenci et al. 2010). The current therapeutics used for HCC treatment involves surgical 86 
resection, transplantation and/or systemic chemotherapy; however, surgery and 87 
transplantation may not be appropriate for many patients and chemotherapy often fails 88 
(Liu et al. 2014). Chemotherapy is also constrained by its toxicity, significant resistance 89 
to available chemotherapeutic agents and side effects, including neutropenia and 90 
myelosuppression (Chau et al. 2006). Current studies involved in developing effective 91 
cancer prevention approaches have focused on the use of bioactive natural agents that 92 
may have less adverse effects and can exert selective cytoxicity against cancer cells 93 
(Ghate et al. 2014).  94 
The chemical and biological diversity of the marine environment is immeasurable and 95 
therefore is an extraordinary resource for the discovery of novel anticancer drugs. Brown 96 
algae are a rich source of secondary metabolites displaying a wide variety of bioactivities 97 
with important features for pharmaceutical purposes. Cystoseira tamariscifolia has 98 
demonstrated interesting biological activities such as antibacterial, antifungal, 99 
antiprotozoal, cell division inhibition, anti-inflammatory, antioxidant and cytotoxic 100 
properties (Bennamara et al. 1999, Spavieri et al. 2010, Lopes et al. 2012, Andrade et al. 101 
2013). These properties have been ascribed to the presence of different classes of 102 
molecules that were identified in C. tamariscifolia, such as phlorotannins 103 
(fucophloroethol, fucodiphloroethol, fucotriphloroethol, 7-phloroeckol, 104 
phlorofucofuroeckol and bieckol/dieckol), phloroglucinol, proline, -sitosterol, 105 
Código de campo alterado
Código de campo alterado
Código de campo alterado
Código de campo alterado
Código de campo alterado
Código de campo alterado
Código de campo alterado
Código de campo alterado
5 
 
fucosterol, and diverse fatty acids (Ferreres et al. 2012, Andrade et al. 2013, Vizetto-106 
Duarte et al. 2015). As C. tamariscifolia extracts have previously demonstrated cytotoxic 107 
potential, in this study we describe the identification of isololiolide, a known carotenoid 108 
metabolite, as a selective cytotoxic compound that was isolated from the brown 109 
macroalga Cystoseira tamariscifolia for the first time. Here we show evidence that 110 
exposure of hepatocarcinoma HepG2 cells to isololiolide is associated with changes in 111 
the expression of p53, PARP, Bcl-2 and procaspase-3. These results might explain the 112 
dramatic suppression of the S phase as well as the induction of apoptosis caused by this 113 
monoterpene. 114 
 115 
Material and methods 116 
Chemicals and reagents 117 
Hexane and ethyl acetate were purchased from Prolabo (VWR International, Leuven, 118 
Belgium). Merck (Darmstadt, Germany) supplied dimethyl sulfoxide (DMSO). Roswell 119 
Park Memorial Institute medium (RPMI), Dulbecco's Modified Eagle's medium 120 
(DMEM), fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin were 121 
obtained from Lonza Ibérica (Barcelona, Spain). 3-(4,5-dimethylthiazol-2-yl)-2,5-122 
diphenyltetrazolium bromide (MTT) was obtained from Calbiochem. Primary antibodies 123 
for poly (ADP-ribose) polymerase (PARP), p53, Bcl-2, actin and respective secondary 124 
antibodies were from Santa Cruz Biotechnology Inc., Heidelberg, Germany. FITC-125 
conjugated annexin V/ propidium iodide (PI) assay kit was acquired from Cayman 126 
Chemical Company, USA. Silica gel (Merck, 40-63 µm mesh) was used for column 127 
chromatographic separation, while silica gel 60 PF254 (Merck) was used for analytical 128 
(0.25 mm) TLC. CDCl3 (Aldrich) was used as solvent for 
1H and 13C NMR spectra 129 
acquisition and TMS (Aldrich) was used as internal standard. 1D and 2D NMR spectra 130 
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were recorded at Bruker Digital Avance 800 MHz spectrometer. Additional reagents and 131 
necessary solvents were purchased from VWR International (Leuven, Belgium). 132 
 133 
Sampling 134 
Cystoseira tamariscifolia was collected in the middle/lower intertidal areas, during the 135 
low tide, between May and September 2012 on the Portuguese coast. Biomass was rinsed 136 
with distilled water and macroscopic epiphytes and extraneous matter were carefully 137 
removed. Identification of specimens was made by Dr Aschwin Engelen (Centre of 138 
Marine Sciences, University of Algarve, Portugal) and Dr Javier Cremades Ugarte 139 
(Facultade de Ciencias, University of A Coruña) and a voucher specimen of C. 140 
tamariscifolia (code number MB016) was deposited at the Centre of Marine Sciences 141 
(CCMAR), University of Algarve. Samples were freeze-dried and stored at -20 °C until 142 
the extraction procedure. 143 
 144 
Extraction 145 
Biomass was mixed with hexane (1:10, w/v) and homogenized for 2 minutes using a 146 
disperser IKA T10B Ultra-Turrax at room temperature (RT). The tubes were then 147 
vortexed for 1 minute, centrifuged (5000 g, 10 minutes, RT) and the supernatants 148 
recovered. The extraction procedure was repeated 3 times and the supernatants combined 149 
and filtered. The extract was dried at 40 ºC under vacuum and dissolved in DMSO for 150 
biological activities screening or in the adequate solvent for chemical characterization, 151 
aliquoted and stored (-20 °C).   152 
 153 
 154 
 155 
Isolation and elucidation of isololiolide  156 
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C. tamariscifolia hexane extract (9 g) was fractionated by column chromatography (2.5 157 
cm × 18 cm) over silica gel (SiO2) using increasing amounts of EtOAc in hexane (9:1; 158 
85:15; 4:1; 75:25; 7:3; 3:2; 1:1) and increasing amounts of MeOH in EtOAc (9:1; 8:1; 159 
5:1; 2:1; 1:1), MeOH (100%) and H2O (100%) as eluents. This procedure afforded 57 160 
fractions, which were analyzed by TLC and pooled together in 21 groups (A – U). 161 
Fraction 14 (70 mg) was re-fractionated over SiO2 eluted with hexane (100 %); 162 
hexane/EtOAc (9:1, 8:2, 7.5:2.5, 7:3, 6.5:3.5, 6:4, 5.5:4.5, 1:1, 4:6), EtOAc (100 %) and 163 
MeOH (100 %) to afford 151 fractions which were pooled together in 9 groups after TLC 164 
analysis. Group 6 – 8, obtained from the hexane/ EtOAc elution (6:4 through 1:1), was 165 
purified by reverse phase preparative HPLC to afford 3 mg of isololiolide. 166 
Isololiolide. Pale yellow oil;1H NMR (800 MHz, CDCl3, TMS, ppm) δ 5.71 (1H, s, H-7), 167 
4.21 (1H, m, H-3), 2.55 (2H, br d, J = 2.4 Hz, H-4), 2.03 (1H, br d, J = 2.4 Hz, H-2), 1.59 168 
(3H, s, H-11), 1.23 (3H, s, H-10), 1.21 (3H, s, H-9). 13C-NMR  (200 MHz, CDCl3, TMS, 169 
ppm): 181.2 (C-6), 171.5 (C-8), 113.3 (C-7), 86.4 (C-5), 65.1 (C-3), 49.8 (C-2), 47.9 (C-170 
4), 35.0 (C-1), 29.9 (C-9), 25.6 (C-11), 25.1 (C-10); HRESIMS m/z 219.0993 [M + Na]+ 171 
(calc to C11H16O3Na 219.0997).          172 
 173 
Cell culture 174 
HepG2 cells (human hepatocellular carcinoma) were maintained in RPMI-1640 culture 175 
media supplemented with glucose (1000 mg/ml), 10% FBS, L-glutamine (2 mM), 176 
penicillin (50 U/ml) and streptomycin (50 µg/ml). MRC-5 and HFF-1 human fibroblasts, 177 
AGS human gastric cancer, HCT-15 human colon cancer cells were grown in DMEM 178 
culture media supplemented with glucose (1000 mg/ml), 10% FBS, L-glutamine (2 mM), 179 
penicillin (50 U/ml) and streptomycin (50 µg/ml). Cell lines were grown in an incubator 180 
at 37 ºC and 5.0% CO2 in humidified atmosphere. 181 
 182 
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Anti-proliferative assay 183 
In vitro cytotoxic activity of isololiolide was assessed by the MTT colorimetric assay. 184 
Hepatocarcinoma HepG2, gastric cancer AGS and colon cancer HCT-15, and also non-185 
tumoral cells (MRC-5 and HFF-1 human fibroblasts) were seeded at a density of 5 × 103 186 
cells/well on 96-well plates and incubated for 24 h at 37 °C in 5.0% CO2. The effect of 187 
isololiolide was evaluated on the viability of these cells and the half maximal inhibitory 188 
concentration (IC50) was calculated upon a 72 h incubation period. Positive control cells 189 
were treated with etoposide, while negative control cells were treated with DMSO at the 190 
highest concentration used in test wells (0.5%, v/v). The selectivity of the compound was 191 
estimated using the following equation: Selectivity = CT/CNT, where CT and CNT 192 
indicate the compound-induced cytotoxicity on tumoral cells and on non-tumoral cells, 193 
respectively (Oh et al., 2010). 194 
 195 
Cell cycle distribution analysis 196 
HepG2 cells were plated at a density of 5 × 104 cells/ml in 6-well plates and incubated 197 
with complete medium only (blank), medium with the solvent DMSO (control, 0.5% v/v) 198 
or with isololiolide at IC50 concentration (13.15 µM), which was previously determined 199 
by the MTT assay. Cells were harvested following 72 h incubation and further processed 200 
for cell cycle analysis. Cellular DNA content for cell cycle distribution analysis was 201 
evaluated using an Epics XL-MCL Coulter flow cytometer plotting at least 10000 events 202 
per sample. Cell cycle distribution data analysis was subsequently performed using the 203 
FlowJo 7.2 software (Tree Star, Ashland, USA).  204 
 205 
 206 
 207 
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Apoptosis detection 208 
HepG2 cells were plated at a concentration of 5 × 104 cells/ml in 6-well plates and 209 
incubated with complete medium only (blank), medium with the solvent DMSO (control, 210 
0.5% v/v), or with isololiolide at IC50 concentration (13.15 µM) for 72 h. Induction of 211 
apoptosis was evaluated by the annexin V-FITC/PI apoptosis Kit (Bender MedSystems, 212 
Vienna, Austria) according to the manufacturer’s instructions. Measurement of annexin 213 
V binding due to phosphatidylserine externalization was analyzed using an Epics XL-214 
MCL Coulter flow cytometer plotting at least 20 000 events per sample. Apoptotic data 215 
analysis was subsequently performed using the FlowJo 7.2 software (Tree Star, Ashland, 216 
USA).  217 
 218 
Protein expression analysis 219 
For the analysis of protein expression, HepG2 cells were treated with complete medium 220 
(blank), medium with the solvent (DMSO) or with loliolide at the IC50 concentration 221 
(13.15 µM), and incubated for 24, 48 and 72 h. After each incubation period cells were 222 
lysed in Winman’s buffer (1% NP-40, 0.1 M Tris–HCl pH 8.0, 0.15 M NaCl and 5 mM 223 
EDTA) with EDTA-free protease inhibitor cocktail (Boehringer, Mannheim, Germany). 224 
Proteins were quantified using the DC Protein Assay Kit (BioRad, Hercules, CA, USA) 225 
and separated in 12% tris-glycine sodium dodecyl sulphate (SDS)–polyacrylamide gel. 226 
Proteins were then transferred to a nitro-cellulose membrane (GE Healthcare, Madrid, 227 
Spain). The membranes were incubated with the following primary antibodies for PARP 228 
(1:4000), actin (1:2000), p53 (1:250), Bcl-2 (1:200) and procaspase-3 (1:2000), and 229 
further incubated with the appropriate secondary antibodies conjugated with horseradish 230 
peroxidase (HRP) diluted 1:2000 in 5% non-fat dried milk in T-TBS. The signal was 231 
10 
 
detected with the Amersham ECL kit (GE Healthcare). Hyperfilm ECL (GE Healthcare) 232 
and Kodak GBX developer and fixer twin pack (Sigma). 233 
 234 
Statistical analysis 235 
Results were expressed as mean ± standard error of the mean (SEM). Analysis of variance 236 
(ANOVA) was assessed using the SPSS statistical package for Windows (release 15.0, 237 
SPSS Inc.), and significance between means was analyzed by the Tukey HSD test (p < 238 
0.05). IC50 values were calculated by sigmoidal fitting of the data using GraphPad Prism 239 
v. 5.0 (GraphPad Software, Inc., La Jolla, CA). Statistical analysis was performed by the 240 
non-parametric Friedman’s test followed by Dunn’s Post-test using GraphPad Prism 5 241 
software. P values  < 0.05 were considered as statistically significant. 242 
 243 
Results and discussion 244 
Characterization of isololiolide 245 
HRESIMS of the isolated compound showed a [M + Na]+ quasi-molecular ion peak at 246 
m/z 219.0993, indicating the molecular formula C11H16O3, with four unsaturations. Its 
1H 247 
NMR spectrum displayed, despite other signals, peaks assigned to hydrogens of three 248 
methyl groups at H 1.21 (s, 3H), 1.23 (s, 3H) and 1.59 (s, 3H), one olefinic hydrogen at 249 
H 5.71 (s, 1H) and one oxymethine hydrogen at H 4.13 (m, 1H). The 13C and DEPT 135 250 
showed eleven peaks assigned to three methyl, two methylene, two methine and four 251 
quaternary carbons, including one -unsaturated carbonyl group at C 171.5 (C-8), 252 
113.3 (C-7) and 181.2 (C-8) and one carbinolic carbon at C 65.1 (C-3). HMBC spectrum 253 
showed cross peaks between the signals at H-11 with C-4/C-5/C-6, H-9 with C-1/C-6/C-254 
10, H-10 with C-2/C-6/C-9 and H-7 with C-5/C-6/C-8. Isololiolide (Fig. 1) was identified 255 
comparing the obtained data with that reported in the literature (Kimura and Maki 2002).  256 Código de campo alterado
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 257 
Anti-proliferative activity of isololiolide in tumoral and non-tumoral cell lines 258 
Isololiolide obtained from the C. tamariscifolia hexane extract was tested on human 259 
hepatocellular carcinoma cells (HepG2), gastric cancer cells (AGS) and colon cancer cell 260 
line (HCT-15). Additionally, the anti-proliferative activity of the compounds was 261 
evaluated in human fibroblasts (MRC-5 and HFF-1). The compound proved to be 262 
cytotoxic against the different tumoral cell lines, namely AGS (IC50 = 32.36 µM), HCT-263 
15 (IC50 = 23.59 µM) and especially HepG2 cells (IC50 = 13.15 µM; Table 1), showing 264 
selectivity indices (SI) of up to 86 and 47 against MRC-5 and HFF-1 fibroblasts, 265 
respectively (Table 1). The cytotoxic effect of this molecule towards HepG2 cells was 266 
particularly evident, whereas no significant toxic effect was observed in MRC-5 or HFF-267 
1 human fibroblasts. Interestingly, extracts from C. tamariscifolia had previously 268 
demonstrated antiproliferative potential against Daudi (human Burkitt’s lymphoma), 269 
Jurkat (human leukemic T cell lymphoblast) and K562 (human chronic myelogenous 270 
leukemia) cells (Zubia et al. 2009). Isololiolide has been described as a carotenoid 271 
metabolite whose precursor is zeaxanthin (Repeta 1989). Carotenoids, such as 272 
zeaxanthin, lycopene and astaxanthin have been previously described as modulators of 273 
growth factors that play important roles in cell cycle regulation and carcinogenesis (Bi et 274 
al. 2013, Alvarez et al. 2014). Moreover, it has been previously demonstrated that 275 
breakdown products of carotenoids (e.g. 3-OH-β-apo-10’-carotenal and apo-10’-276 
lycopenal) might act as chemotherapeutic agents against breast and hepatic cancer 277 
(Tibaduiza et al. 2002, Ip et al. 2014). Loliolide, an isololiolide isomer, is also a well-278 
known carotenoid metabolite derived from the breakdown from fucoxanthin able to 279 
inhibit algal growth (Taylor and Burden 1970). On the other hand, isololiolide has been 280 
previously isolated from brown algae namely from Undaria pinnatifida (Kimura and 281 
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Maki 2002), Dictyopteris divaricata (Song et al. 2004) and Homoeostrichus formosana 282 
(Fang et al. 2015). However, this is the first report describing the occurrence of 283 
isololiolide in C. tamariscifolia.  284 
 285 
Effects on cell cycle profile 286 
Because of the potential application of carotenoid breakdown products in cancer 287 
therapeutics and the observed cytoxicity in HepG2 cells, we researched the effectiveness 288 
of isololiolide in arresting the cell cycle in the latter hepatocarcinoma cell line. For this 289 
purpose, HepG2 cells were incubated with isololiolide at 13.15 µM (IC50) for 72 h and its 290 
effect on cell cycle distribution was studied. Analysis of the cell cycle was performed by 291 
flow cytometry and the results showed that this monoterpenoid completely disrupted the 292 
normal HepG2 cell cycle. In fact, isololiolide induced G2/M cell cycle arrest along with 293 
a concomitant decrease in the percentage of cells in the S phase (Fig. 2AA) and this effect 294 
was sustained throughout the 72 h treatment. In fact, the percentage of cells in G2/M 295 
phase was 15.09 % and 14.91 % for the control and DMSO 0.5 %, respectively, increasing 296 
to 57.95 % upon treatment with isololiolide at 13.15 µM for 72 h (Fig. 2BB). In addition, 297 
there were virtually no cells in the S phase after the same incubation. Taken together, 298 
these results suggest that isololiolide affects the molecular pathways monitoring and 299 
controlling cell cycle progression by arresting the cells at the G2/M checkpoint. The cell 300 
cycle checkpoints play an important role in the control system by sensing defects 301 
occurring during essential processes, such as DNA replication or chromosome 302 
segregation, inducing a cell cycle arrest until the defects detected are repaired (Malumbres 303 
2012).  304 
 305 
Apoptosis induction by isololiode treatment 306 
Código de campo alterado
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The annexin V-FITC/PI flow cytometry assay was used in order to determine if 307 
isololiolide was inducing apoptosis in HepG2 cells. Bivariate staining using annexin V-308 
FITC/PI further demonstrated that isololiolide induced apoptosis at the IC50 concentration 309 
(Fig. 3AA). HepG2 cells were treated with isololiolide for 72 h and a significant increase 310 
(P < 0.01) in the percentage of apoptotic cells was observed, from 6.9 % in untreated 311 
cells, to 29.1 % in cells treated with isololiolide (Fig. 3BB). Apoptosis is described as an 312 
active process of programmed cellular death that avoids an exacerbated inflammatory 313 
response (Fink and Cookson 2005) and is associated with responses to cancer therapy. In 314 
fact, it is widely described that resistance to apoptosis is one of the hallmarks of cancer 315 
cells (Hanahan and Weinberg 2011). This resistance enables cancerous cells to survive 316 
and divide even in the presence of endogenous proapoptotic stimuli. Therefore, induction 317 
of apoptosis is an important mechanism in selecting novel molecules with anti-cancer 318 
potential. 319 
 320 
Western blot analysis of apoptosis-related proteins  321 
Based on the results obtained with annexin V-FITC demonstrating that apoptosis is 322 
occurring, the expression of apoptosis-related proteins was evaluated by assessing 323 
procaspase-3, PARP, Bcl-2 and p53 protein levels expression in HepG2 cells incubated 324 
with complete medium (control), vehicle (DMSO 0.5% v/v) or isololiolide (13.15 µM).   325 
Concerning caspase-3, a decrease in procaspase-3 expression upon isololiolide treatment 326 
at 24 h was measured (Fig. 4, P < 0.05). In human cells, apoptosis takes place through a 327 
cascade of events involving two main pathways: the intrinsic and the extrinsic pathways 328 
(Kroemer et al. 2007). Both pathways ultimately converge on the activation of 329 
procaspases (primarily procaspase-3, but also procaspase-7 and procaspase-6) to 330 
caspases, which are the cysteine proteases that cleave their protein substrates within the 331 
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cell. Effector caspase-3 zymogen (or procaspase-3) exists within the cytosol as an inactive 332 
dimer (Boatright and Salvesen 2003). It is activated by limited proteolysis within the 333 
interdomain linker, which is carried out by an initiator caspase or occasionally by other 334 
proteases under specific circumstances. At cytosolic concentrations in human cells, the 335 
caspase-3 zymogens are already dimers, but cleavage within their respective linker 336 
segments is required for activation (Boatright and Salvesen 2003). Therefore, a decrease 337 
in procaspase-3 levels is due to its proteolysis, leading to caspase-3 activation. Our results 338 
showed that incubation of HepG2 cells with isololiolide resulted in a 2-fold decrease of 339 
procaspase-3 levels, strongly suggesting that procaspase-3 was processed to caspase-3. 340 
In addition, concentrations of procaspase-3 in certain cancerous cells are significantly 341 
higher than those in non-cancerous controls (Putt et al. 2006). 342 
PARP cleavage increased about 4-fold upon isololiolide incubation at 13.15 µM for 24  343 
h (Fig. 5, P < 0.01). Interestingly, this increment seems to be time-dependent as shown in 344 
Fig. 5. PARP plays an active role in key biological processes, such as transcription and 345 
cell cycle regulation, response to DNA damage, apoptosis and maintenance of genome 346 
integrity. The presence of cleaved PARP is one of the most used biomarkers for the 347 
detection of apoptosis (Duriez and Shah 1997). Moreover, PARP is a substrate of caspase-348 
3 and its cleavage into two fragments has been considered to be indicative of functional 349 
caspase activation (Bressenot et al. 2009). Cleaved PARP was observed after treatment 350 
with isololiolide, in a time-dependent manner. In fact, (Soldani et al. 2001) reported that 351 
PARP proteolysis by caspase is a very early response to the apoptotic stimulus.  352 
Western blot performed in the cell lysates obtained from isololiolide-treated cells showed 353 
increased expression of p53 at 24 h (Fig. 6, P < 0.05 vs. DMSO 0.5 %). The tumor 354 
suppressor protein p53 acts as a key player in tumor suppression, as it induces apoptosis 355 
and cell cycle arrest as well as suppress angiogenesis (Amaral et al. 2010). p53 is usually 356 
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responsible for activating DNA repair proteins when DNA has extensive damage, 357 
arresting the cell cycle at regulation points or initiating apoptosis if DNA damage shows 358 
to be irreparable. Interestingly, p53 not only induces G1 cell cycle arrest, but it is also 359 
described to act at the G2/M checkpoint, preventing cells from entering mitosis if DNA 360 
damage is found (Taylor and Stark 2001). Furthermore, p53 has the ability to activate the 361 
transcription of various pro-apoptotic genes, including those encoding members of the 362 
Bcl-2 family (Roos and Kaina 2006). 363 
Our results showed that anti-apoptotic Bcl-2 protein expression remained unchanged after 364 
24 h of incubation with isololiolide, decreasing after 48 h with the same treatment (Fig. 365 
7,  P < 0.05 vs DMSO 0.5 %). Overexpression of anti-apoptotic Bcl-2 family members 366 
have been associated with chemotherapy resistance in various human cancers, and 367 
targeting the anti-apoptotic Bcl-2 family members have shown promising results in 368 
preclinical studies (Kang and Reynolds 2009). Bcl-2 suppresses apoptosis by binding to 369 
Bax or Bak. It is described that inhibiting the anti-apoptotic Bcl-2 could sensitize tumor 370 
cells to chemo- and radiotherapy. Therefore, decrease of Bcl-2 levels may be a plan of 371 
choice to increase treatment efficacy. Furthermore, it was suggested that p53 also 372 
modulates Bcl-2 by downregulation (Kirkin et al. 2004). 373 
In summary, application of isololiode resulted in the increase on caspase-3 expression, 374 
concomitant with increase in PARP cleavage and p53 expression. Corresponding down-375 
regulation of anti-apoptotic/pro-survival Bcl-2 protein was also detected.  376 
Indeed, molecules that activate caspase-3 and p53, cleave PARP or bind to Bcl-2 have 377 
shown potential in cell culture and preclinical models of cancer (Peterson et al. 2009). 378 
Taken together, our results strongly suggest that isololiolide is able to exert potent anti-379 
proliferative properties, significantly promoting cell cycle arrest in S phase and inducing 380 
cellular apoptosis in a human-derived hepatocarcinoma cell line. 381 
Código de campo alterado
Código de campo alterado
Código de campo alterado
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 382 
Conclusions 383 
This report demonstrates for the first time the in vitro anti-tumoral activity of isololiolide 384 
obtained from C. tamariscifolia hexane extract against hepatocarcinoma through the 385 
induction of apoptosis by altering the expression of proteins important to the apoptotic 386 
cascade. As isololiolide exhibited no cytotoxicity on non-tumoral human fibroblasts 387 
under the same conditions, it would be important in the future to perform structure-388 
activity relationships (SARs) analysis for further studies. In addition, it may provide novel 389 
clues as to how carotenoids and their metabolites play a role in preventing and/or slowing 390 
down cancer progression. 391 
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Figure legends 542 
 543 
Fig. 1. Chemical structure of isololiolide. 544 
 545 
Fig. 2. HepG2 cell cycle analysis (A) from control (incubation with complete medium 546 
only), DMSO (0.5% v/v) or isololiolide (13.15 µM) treatment for 72 h. Percentage of 547 
cells in G1, S and G2/M phases upon the treatments described above (B). 548 
 549 
Fig. 3. Flow cytometric analysis (A) and the proportion of apoptotic (B) HepG2 cells 550 
treated for 72 h with control (incubation with complete medium only), DMSO (0.5% v/v) 551 
or isololiolide (13.15 µM) for 72 h stained for annexin V-FITC/PI. **P < 0.01 vs. DMSO 552 
0.5 %. 553 
 554 
Fig. 4. Procaspase-3 expression levels upon incubation with complete medium (control), vehicle 555 
(DMSO 0.5 %) or isololiolide (13.15 µM) at 24 h. *P < 0.05 vs. DMSO 0.5 %. 556 
 557 
Fig. 5. Full length (PARP) and cleaved PARP (PARP*) expression levels upon incubation with 558 
complete medium (control), vehicle (DMSO 0.5 %) or isololiolide (13.15 µM) at 24, 48 and 72 559 
h. *P < 0.05, **P < 0.01 vs. DMSO 0.5 %. 560 
 561 
Fig. 6. p53 expression levels upon incubation with complete medium (control), vehicle (DMSO 562 
0.5 %) or isololiolide (13.15 µM) at 24 h.*P < 0.05 vs. DMSO 0.5 %. 563 
 564 
Fig. 7. Bcl-2 expression levels upon incubation with complete medium (control), vehicle (DMSO 565 
0.5 %) or isololiolide (13.15 µM) at 24 and 48 h. *P < 0.05 vs. DMSO 0.5 %. 566 
 567 
 568 
